glp-1 receptor agonists weight loss glp-1_analogs [TUSOM GLP1 Receptor Agonists—Effects beyond Obesity

Yaribeygi H, Maleki M, Butler AE, et al

Further reading on observed adverse signal profiles from the investigational phase 2 programme is available in the Retatrutide Side Effects: Detailed Guide with Clinical Trial Insights 2026 article, which summarises published tolerability data for research planning purposes

The NOS evaluates studies based on three criteria: (1) selection of study groups (representativeness, ascertainment of exposure, and demonstration that the outcome was not present at baseline), (2) comparability of groups (control for confounding factors), and (3) assessment of outcome (adequacy of follow-up and blinding of outcome assessment)

I meet the BMI and have predibetes and hypertension

Measurement of GLP-1

Real world efficacy analysis of switch from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: REALISE-DM Study